In Europe, extracts from Harpagophytum procumbens and Salix species are widely used for the treatment of rheumatïc pain. Déclaration of the quantity of active principles helps to optimize treatment success. For both herbal médicinal products, pharmacological and clinical studies hâve proven antirheumafic effectiveness which is superior to placebo and equally effective compared to synthetic médication. Treatment of osteoarthritic and low back pain with Harpagophytum procumbens and Salix extracts is associated with a low incidence ' of adverse events lower than that known from NSAIDs. In terms of quality, safety and efficacy, Harpagophytum procumbens and Salix : extract préparations may fulfill the requirements that characterize synthetic médication.
Biopharmaceutical quality of Harpagophytum préparations
The monographs of the European Scientific Coopérative on Phytotherapy (ESCOP, 1 996) refer to pharmacopeia définitions of herbal material. Requirements for drug préparations include the eut, dried secondary root tubers that contain at least 2.2% of iridoid glycosides or 1 .2% harpagoside for Harpagophytum procumbens and the dried bark of young branches which should contain not less than 1% of total salicin for Salix species.
Harpagophytum préparations
For the treatment of painful arthrosis or tendinitis, the Harpagophytum ESCOP Monograph (1 996) recommends 1 .5 -3.0 g drug in décoction three times per day or équivalent aqueous or hydroalcoholic extracts. With 9 g crude 1 % drug patients consume 1 00 mg harpagoside (Chrubasik ef ai, 1 996a ). An analysis of the Harpagophytum préparations available in Germany 1996 re¬ vealed that the mean harpagoside content of the tablets varied bet¬ ween 1 .5 and 9.3 mg with a daily consumption of harpagoside between 0.2 and 50 mg, respectively (Chrubasik et ai, 1 996b) . Tea (aqueous extract) of 9 g crude drug contains a mean of 1 80 mg harpagoside, depending on the harpagoside content of the drug, which varied in the tea drugs 1996 between 1.1 and 3.6% (Chrubasik et ai, 1 996a). Producer extracts with up to 2% harpa¬ goside (Chrubasik et ai, 1 996c) provide tablets with 50 mg har¬ pagoside or less in the daily dosage. A spécial Harpagophytum ex tract, WS 1531* (drug extract ratio 6-9:1, harpagoside enriched, minimum 5%), has recently been used for a dose-finding study (daily dosage of harpagoside 50 and 1 00 mg) (Chrubasik et 
Salix préparations
For the treatment of feverish conditions, symptomatic treatment of mild rheumatic complaints, reliefs of pain, including mild headache, the Salix ESCOP Monograph (1997) recommends 3 -6 g of powdered drug or extracts équivalent to up to 240 mg salicin, a prodrug of salicylate metabolites. This particular salicin dose is bioequivalent to 50 mg acetylsalicylate (Schmid, 1 998), a cardioprotective rather than a pain-relieving dose.
Effect mechanisms
Herbal médicinal products for the treatment of pain hâve a broader effect mechanism than synthetic antirheumafic drugs that are more or less sélective cyclooxygenase inhibitors. Harpagophytum extract inhibits not only both arachidonic acid metabolism pathways, the cyclo-oxygenase and the lipoxygenase (Tippler et ai, 1 997) but also cytokine release (TNFa) (Kammerer and Fiebig, 2000) and may exert still unknown effects. Likewise, Salix extract interacts with both both arachidonic acid metabolism pathways, cytokine release and provides antioxidative activity (Chrubasik et ai, 2000 (Chrubasik et ai, 1 996d) included 1 1 8 patients suffering for longer than 6 months from chronic low back pain not attributable to identifiable causes. Upon their written informed consent, they received either 2400 mg Harpagophytum extract (drug-extract ratio 2.5: 1 ) with 50 mg harpagoside per day or a placebo. Prior to treatment, the groups were comparable with regard to their history and biochemical data, circulafory and laboratory parameters, as well as the Arhus low back pain index (Manniche et ai, 1 994) and its scores for pain, invalidity and physical impairment. After 4 weeks, the mé¬ dian Arhus low back pain index had improved by 20% in the Harpagophytum group and by 8% in the placebo group (p < 0,059). This significant trend of effectiveness was based on a si¬ gnificant decrease in the pain index (p = 0,016). In patients with pseudoradiating pain into the leg(s), the médian effect of Harpagophytum extract was like fhat of placebo. However, in pa¬ tients suffering from pain not pseudoradiating info the leg(s), the pain index decrease was 25% in the Harpagophytum group and zéro in the placebo group (Fig. 4) . Nine of 54 patients receiving Harpagophytum extract (a total of 20%) were completely pain-free in the fourth week of treatment, as compared one patient (2%) in the placebo group (p = 0,008). Only minor and nonspecific ad¬ verse effects occurred during the Harpagophytum treatment.
Another double-blind study (Chrubasik et There was no significant différence at baseline in fhe efficacy as¬ sessment between the two treatment groups. The primary efficacy parameter "spontaneous pain" showed a significant improvement in both treatment groups but there was no statistical différence bet¬ ween the two groups. Likewise, both treatments resulted in impro¬ vement of functional parameters of the knee or of the hip. At completion of the four-month treatment phase, patients taking Harpagophytum procumbens were using significantly less NSAIDs and antalgic drugs. Significant less patients in the Harpagophytum procumbens group (n=10) reported at least one adverse reaction imputable to the treatment compared to the patients in the diacer¬ hein group (n=21 ). The most common adverse events reported were gastro-intestinal disfurbances.
Salix species
Five exploratory (ESCOP, 1 997; and 2 confirmatory studies give évidence for the antirheumafic efficacy of Salix préparations. A double-blind study investigated 78 inpatienfs of a clinic for rheumatic diseases (Schmid, 1998) . They suffered from osteoarthritis of the knee and/or hip joint, as verified by the ARA criteria. After a wash-out period of four days, patients received daily 1360mg Salix bark extract (in form of coated tablets) or placebo for two weeks. Verum médication corresponded to 240 mg salicin/day. An analgésie effect of the verum médication was obs¬ erved by monitoring the change of the WOMAC pain index from day 0 to day 1 4 as the main study criterion. Using 1 0 cm visual analogue scales, a statistically significant différence (p<0.05) bet¬ ween verum and placebo group was observed both in the intentionto-treat population (n = 78 patients) and in the per-protocol popu¬ lation (n = 68 patients). Daily 1 0 cm VAS pain scales, and final overall assessments by patient and doctor, were used as secondary cri¬ teria and confirmed the positve effect of the verum médication. Only minor adverse events occurred.
In another placebo-controlled, randomised, double-blind study (Chrubasik et ai, 2000) oral Salix bark extract with 1 20 and 240 mg salicin per day was compared with placebo over 4 weeks. 21 0 patients suffering from exacerbations of chronic low back pain and reporting current pain of more than 5 out of 1 0 on a visual ana¬ logue scale were included. Patients were allowed tramadol as the sole rescue médication and the principle outcome measure was the number of patients who were pain-free without tramadol for 5 days out of the last week. The treatment and placebo groups were well matched at baseline in 1 14 of 120 clinical features. Patients in both Salix groups tended to hâve higher Arhuse scores than those receiving placebo. Those receiving the larger dose of extract tended to hâve suffered pain for longer than those in the other groups, with osteoporosis contributing more to the overall pain; more of them suffered from dépression and their Beck dépression score tended to be higher and more had previously tried opioids and a third of them had changed their occupation because of unbearable pain. A total of 1 91 patients completed the study. The respective numbers of pain-free patients were 4, 1 5 and 27 in the placebo group (P), the Salix bark extract groups with 1 20 mg salicin and 240 mg salicin, respectively (p<0.001, one-tailed Cochrane-Armitage test, intention-to-treat analysis on 210 patients with "drop-outs" considered as "non-responders" to treatment). Neither radiation into the leg(s) nor the duration of the propensity to low back pain nor the dura¬ tion of the exacerbation affected the response. A significant response in the Salix group with 240 mg salicin was évident after only one week of treatment. For each week of the study, significantly more patients in the placebo group required tramadol. There was no évidence for Salix bark-related side-effects, though one patient suffered a severe allergie reaction, possibly to the extract.
Conclusions
The ['Harpagophytum (1996) (Chrubasik et ai, 1999 placebo (p < 0,059). Ce ré¬ sultat positif quant à l'efficacité probable de la drogue se fondait sur une baisse importante de l'indice de douleur (p = 0,01 6). Chez les patients souffrant de douleurs pseudo-irradiantes dans une/les jambe(s), la valeur médiane de l'efficacité de l'extrait d'Harpagophytum était comparable à celle du placebo.
Cependant, chez les patients souffrant de douleurs non pseudo-ir¬ radiantes dans une ou les jambe(s), la baisse de l'indice de douleur était de 25 % pour le groupe traité à ['Harpagophytum et de zéro pour le groupe ayant reçu un placebo (Fig. 4) . Neuf des 54 patients ayant absorbé l'extrait d' Harpagophytum (au total 20 %) ne souf¬ fraient absolument plus après la quatrième semaine de traitement, contre un seul patient (2 %) dans le groupe ayant reçu un placebo (p = 0,008). Seuls des effets nocifs mineurs et non spécifiques ont été relevés au cours du traitement à Y Harpagophytum. 
